In the phase 1/2 study, CT1812 did not demonstrate significant differences in cognitive clinical scores; however, it showed a positive trend in MRI volumetric measures indicating tissue protection, thereby supporting its further clinical development [ 283 ].Additionally, NeuroadTM demonstrates efficacy and safety in the treatment of AD.
← all excerpts
Inflammatory Bridges: Interconnections Between Alzheimer's Disease and Bone Health.
1
—
—